Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of “Moderate Buy” by Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $51.40.

COAG has been the topic of a number of research analyst reports. Weiss Ratings began coverage on Hemab Therapeutics in a report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Wedbush boosted their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Jefferies Financial Group increased their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Finally, HC Wainwright raised their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th.

Hemab Therapeutics Stock Performance

COAG stock opened at $44.41 on Friday. The stock has a 50-day simple moving average of $45.23. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $55.42. The company has a market cap of $2.07 billion and a price-to-earnings ratio of -1.79.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). On average, equities analysts forecast that Hemab Therapeutics will post -3.09 earnings per share for the current year.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Hemab Therapeutics stock. Braidwell LP acquired a new stake in Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 160,000 shares of the company’s stock, valued at approximately $5,877,000. Braidwell LP owned 0.34% of Hemab Therapeutics as of its most recent filing with the Securities & Exchange Commission.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.